Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
(2016) Journal of Translational Medicine — Vol. 14, n° 1, p. 232 (2016)
Files
boreal_182273.pdf
Open Access - Adobe PDF
- 1.54 MB
Details
- Authors
- Abstract
- Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10-15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing individualized treatment strategies.
- Affiliations
Citations
Seremet, T., Koch, A., Jansen, Y., Schreuer, M., Wilgenhof, S., Del Marmol, V., Liènard, D., Thielemans, K., Schats, K., Kockx, M., Van Criekinge, W., Coulie, P., De Meyer, T., van Baren, N., & Neyns, B. (2016). Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 14(1), 232. https://doi.org/10.1186/s12967-016-0990-x (Original work published 2016)